TG6002, oncolytic virus
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the tumor.
TG6002 aims to attack solid tumors on multiple “fronts” while avoiding the side effects of chemotherapy.
Sale of the rights in China
Tasly Biopharmaceutical Group Co, Ltd. acquired research, development and commercialization rights of the technology of TG6002 (T601) for Greater China in 2018. >>read the press release
First promising results
Transgene is developing TG6002 for the treatment of several solid tumors, such as gastro-intestinal adenocarcinoma (stomach, pancreas and colon). Phase I interim results demonstrate that after IV infusion, TG6002 was detected in the tumor and induced the production of 5-FU. No major SAE have been observed.
Attacking the tumor on several fronts
TG6002 combines several mechanisms of action to:
- directly and selectively destroy the cancer cells (oncolysis) by causing immunogenic cell death;
- induce an immune response,, following the release of antigens during the oncolysis;
- allow the production of chemotherapy (5-FU), directly in the tumor..
Ongoing clinical trials
- September 16, 2021 - Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
- April 9, 2021 - Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
- September 8, 2020 - Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
>> All press releases
Tiphaine Delaunay, et al. Jérémy Béguin, et al.
Molecular Therapy Oncolytics, September 2020 – Read the article and view videos
Molecular Therapy Oncolytics, September 2020 – Read the article
Tiphaine Delaunay, et al.
Jérémy Béguin, et al.